Q-omics provides the consensus-scored BEX5 profile across patient tissues and cancer cell-line models. BEX5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, BEX5 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, BEX5 RNA expression shows 17,040 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, LUAD, and GBM as cancer lineages where BEX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEX5 survival associations across molecular data types. BEX5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEX5 RNA expression–survival associations across cancer types. High BEX5 expression shows favorable associations in OV, ACC, UVM, KIRC, SKCM and LUAD. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for BEX5 RNA expression.
This table summarizes BEX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BEX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEX5 shows lower tumor expression in LUAD, KIRC, LUSC, KIRP and THCA and higher tumor expression in UCEC. The LUAD box plot shows higher BEX5 RNA expression in normal versus tumor tissue (log2 FC = −2.230, t-test p < 0.001).
This table shows molecular features associated with BEX5 in patient tissues and cancer cell lines. In patient samples, BEX5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BEX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
